Share Price | Triochem Products Ltd Stock Analysis & Recommendation

Q: Why is Triochem Products Ltd falling/rising?

As of 17-Jul, the stock price of Triochem Products Ltd is currently at 17.40, showing no change (0.00%). The stock has underperformed significantly compared to the sector, with a performance today that is down by 99.34%. Additionally, the stock has not traded on 5 out of the last 20 days, indicating erratic trading behavior. Triochem Products Ltd is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which suggests a downward trend in its price performance. Furthermore, while the BSE Small Cap index has gained by 1.42%, Triochem's year-to-date performance shows no change, contrasting with the Sensex, which has declined by 8.30% over the same period. This combination of factors indicates that the stock is not rising and is instead experiencing stagnation and underperformance relative to both its sector and broader market indices.

Q: What does Triochem Product do?

Overview: Triochem Products Ltd is engaged in the manufacturing and exporting of pharmaceutical products, APIs, and chemicals, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Micro Cap company.History: Triochem Products Ltd was incorporated on January 17, 1972. The latest quarterly results reported are for March 2026, during which the company reported its net profit.Financial Snapshot: Most recent Net Sales: N/A Most recent Net Profit: 8 Cr (Quarterly Results - Mar 2026) Market-cap value: INR Cr (Micro Cap)Key Metrics: Industry P/E: N/A Dividend Yield: 0.00% Debt-Equity: 0.00 Return on Equity: 0.00% Price to Book: 0.00Contact Details: Address: Sambhava Chambers, 4th Floor Sir P M Road Mumbai Maharashtra : 400001 Tel: 91-22-22663150 Email: investor@triochemproducts.com Website: http://www.triochemproducts.com

Q: Who are in the management team of Triochem Product?

The management team of Triochem Product includes the following individuals:1. Ramu S Deora - Director & Chief Executive Officer2. Sunil S Jhunjhunwala - Independent Director3. S S Sharma - Director4. Girish Kumar Pungalia - Independent Director5. Rajesh Ramu Deora - Director6. Ureca Shirish Shirole - Company Secretary & Compliance Officer7. Grace R. Deora - Non-Executive DirectorIf you have any more questions about the company or its management, feel free to ask!

Q: Who are the peers of the Triochem Product?

Peers: The peers of Triochem Product are Beryl Drugs, Unjha Formul., Decipher Labs, Vivanza Biosci., Ganga Pharma., Brawn Biotech, Shyama Computro., Fabino Enter, and Saroja Pharma In.Quality Snapshot: Below Average management risk is observed at Beryl Drugs, Decipher Labs, Vivanza Biosci., Ganga Pharma., Brawn Biotech, and Fabino Enter, while Average management risk is found at Unjha Formul. and Saroja Pharma In. Shyama Computro. does not qualify for management risk assessment. Growth is Below Average for Beryl Drugs, Decipher Labs, Brawn Biotech, Vivanza Biosci., and Fabino Enter, while Average growth is noted at Ganga Pharma. Unjha Formul. has Below Average growth, and Saroja Pharma In has Below Average growth as well. Shyama Computro. does not qualify for growth assessment. Capital Structure is rated as Good for Unjha Formul., Average for Ganga Pharma., and Below Average for Beryl Drugs, Decipher Labs, Vivanza Biosci., Brawn Biotech, Fabino Enter, and Saroja Pharma In, with Shyama Computro. not qualifying.Return Snapshot: Beryl Drugs has the highest 1-year return at 31.73%, while Vivanza Biosci. has the lowest at -29.75%. Triochem Product's 1-year return is 0.00%, which is lower than Beryl Drugs and higher than Vivanza Biosci. Additionally, the six-month return is negative for Unjha Formul., Decipher Labs, Vivanza Biosci., Ganga Pharma., Brawn Biotech, and Fabino Enter.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

Shareholding (Jun 2026)

FII

0.00%

Held by 0 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

68.65%

Why is Triochem Products Ltd falling/rising?

18-Jul-2026

As of 17-Jul, the stock price of Triochem Products Ltd is at 17.40, with no change and significant underperformance compared to the sector, down 99.34% today. The stock is trading below all major moving averages and has shown stagnation, contrasting with the BSE Small Cap index's gain and the Sensex's decline.

View full answer

Which are the latest news on Triochem Product?

18-Jul-2026

No latest news for Triochem Product found.

What does Triochem Product do?

11-Jun-2026

Triochem Products Ltd manufactures and exports pharmaceutical products, APIs, and chemicals, operating as a Micro Cap company. As of March 2026, it reported a net profit of 8 Cr.

View full answer

Who are in the management team of Triochem Product?

11-Jun-2026

The management team of Triochem Product includes Ramu S Deora (CEO), Sunil S Jhunjhunwala (Independent Director), S S Sharma (Director), Girish Kumar Pungalia (Independent Director), Rajesh Ramu Deora (Director), Ureca Shirish Shirole (Company Secretary), and Grace R. Deora (Non-Executive Director).

View full answer

Who are the peers of the Triochem Product?

11-Jun-2026

Triochem Product's peers include Beryl Drugs, Unjha Formul., Decipher Labs, Vivanza Biosci., Ganga Pharma., Brawn Biotech, Shyama Computro., Fabino Enter, and Saroja Pharma In. Most peers exhibit below-average management risk and growth, with Beryl Drugs showing the highest 1-year return at 31.73% and Vivanza Biosci. the lowest at -29.75%.

View full answer

Who are the top shareholders of the Triochem Product?

17-Jul-2025

The top shareholders of Triochem Product include Rajesh Ramu Deora with 14.69%, Ambernath Plasto Packaging Private Limited at 4.9%, and individual investors holding a combined 15.53%. There are no mutual funds or foreign institutional investors currently involved.

View full answer

When is the next results date for Triochem Product?

16-May-2025

No Upcoming Board Meetings

Compare Triochem Product with Similar Stocks

Shyama Computro.Fabino Enter Brawn Biotech

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

INR Cr (Micro Cap)

P/E

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.00

Return on Equity

0.00%

Price to Book

0.00

Revenue and Profits:

Net Sales:

(Quarterly Results - Mar 2026)

Net Profit:

8 Cr

Total Returns

Total Returns (Price + Dividend)

Company does not have enough history

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

No Recent News for the Company

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018

15-Jul-2026 | Source : BSE

Confirmation Certificate dated 1st July 2026

Compliance-57 (5) : intimation after the end of quarter

15-Jul-2026 | Source : BSE

Not Applicable as no such securities are issued by the Company

Disclosures By Listed Entities Of Defaults On Payment Of Interest/ Repayment Of Principal Amount For Loans Including Revolving Facilities Like Cash Credit From Banks / Financial Institutions

15-Jul-2026 | Source : BSE

Disclosures by listed entities of defaults on payment of interest/ repayment of principal amount for loans including revolving facilities like cash credit from banks / financial institutions

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

No Dividend history available

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

No Data Found

Valuation key factors

No Data Found

Technicals key factors

Indicator

Weekly

Monthly

Technical indicator has not been calculated since the stock has been active for a short period

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jun 2026

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Rajesh Ramu Deora (14.69%)

Highest Public shareholder

Triochem Laboratories Private Limited (4.9%)

Individual Investors Holdings

15.53%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Dec 2025",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 6,507.69% vs 31.58% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.22",
          "val2": "-0.38",
          "chgp": "42.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.08",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "11.17",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "8.33",
          "val2": "-0.13",
          "chgp": "6,507.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is -83.33% vs 89.38% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.78",
          "val2": "-0.60",
          "chgp": "-30.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.22",
          "val2": "-0.12",
          "chgp": "-83.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is -1,066.67% vs 97.74% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.16",
          "val2": "-1.19",
          "chgp": "2.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "-0.35",
          "val2": "-0.03",
          "chgp": "-1,066.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 2,092.50% vs 60.40% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.38",
          "val2": "-1.22",
          "chgp": "-13.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.08",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "11.17",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "7.97",
          "val2": "-0.40",
          "chgp": "2,092.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ

Mar'26

Dec'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-0.22

-0.38

42.11%

Interest

0.08

0.00

Exceptional Items

11.17

0.00

Standalone Net Profit

8.33

-0.13

6,507.69%

Operating Profit Margin (Excl OI)

0.00%

Values in Rs Cr.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Dec 2025

Standalone Net Profit

QoQ Growth in quarter ended Mar 2026 is 6,507.69% vs 31.58% in Dec 2025

All Quarterly Results

Half Yearly Results Snapshot (Standalone) - Sep'25

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-0.78

-0.60

-30.00%

Interest

0.00

Exceptional Items

0.00

Standalone Net Profit

-0.22

-0.12

-83.33%

Operating Profit Margin (Excl OI)

0.00%

Values in Rs Cr.

Compare with Peers

Net Sales

Growth in half year ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Standalone Net Profit

Growth in half year ended Sep 2025 is -83.33% vs 89.38% in Sep 2024

All Half Yearly Results

Nine Monthly Results Snapshot (Standalone) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-1.16

-1.19

2.52%

Interest

0.00

Exceptional Items

0.00

Standalone Net Profit

-0.35

-0.03

-1,066.67%

Operating Profit Margin (Excl OI)

0.00%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in nine months ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Standalone Net Profit

YoY Growth in nine months ended Dec 2025 is -1,066.67% vs 97.74% in Dec 2024

All Nine Monthly Results

Annual Results Snapshot (Standalone) - Mar'26

Mar'26

Mar'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-1.38

-1.22

-13.11%

Interest

0.08

0.00

Exceptional Items

11.17

0.00

Standalone Net Profit

7.97

-0.40

2,092.50%

Operating Profit Margin (Excl OI)

0.00%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2026 is 0.00% vs 0.00% in Mar 2025

Standalone Net Profit

YoY Growth in year ended Mar 2026 is 2,092.50% vs 60.40% in Mar 2025

All Annual Results

Company CV

About Triochem Products Ltd

Triochem Products Ltd

Micro Cap

Pharmaceuticals & Biotechnology

Triochem Products Ltd was incorporated in the year January 17, 1972. The Company is engaged in the business of manufacturer and exporter of pharmaceuticals products, API and chemicals.

Company Coordinates

Company Details

Sambhava Chambers, 4th Floor Sir P M Road Mumbai Maharashtra : 400001

Tel: 91-22-22663150

http://www.triochemproducts.com

investor@triochemproducts.com

Registrar Details

Sharex (India) Pvt Ltd , Unit No.1, Luthra Ind.Premises Andheri Kurla Road, Safed Pool , Mumbai